Item Type | Name |
Academic Article
|
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
|
Concept
|
Adenocarcinoma
|
Concept
|
Adenocarcinoma, Mucinous
|
Academic Article
|
Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer.
|
Academic Article
|
Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.
|
Academic Article
|
A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.
|
Academic Article
|
Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.
|
Academic Article
|
Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer.
|
Academic Article
|
Tumor-node-metastasis staging of pancreatic adenocarcinoma.
|
Academic Article
|
Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.
|
Academic Article
|
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
|
Academic Article
|
Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.
|
Academic Article
|
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
|
Academic Article
|
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection.
|
Academic Article
|
Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.
|
Academic Article
|
Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma.
|
Academic Article
|
SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms.
|
Academic Article
|
Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
|
Academic Article
|
Non-pancreatic periampullary adenocarcinomas: an explanation for favorable prognosis.
|
Academic Article
|
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.
|
Academic Article
|
Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial.
|
Academic Article
|
Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
|
Academic Article
|
Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
|
Academic Article
|
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
|
Academic Article
|
Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.
|
Academic Article
|
Imaging of pancreatic adenocarcinoma: update on staging/resectability.
|
Academic Article
|
Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.
|
Academic Article
|
Treatment of borderline resectable pancreatic cancer.
|
Academic Article
|
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
|
Academic Article
|
Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma.
|
Academic Article
|
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
|
Academic Article
|
Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis.
|
Academic Article
|
Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy.
|
Academic Article
|
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.
|
Academic Article
|
The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.
|
Academic Article
|
Multidisciplinary management of resectable adenocarcinoma of the pancreatic head.
|
Academic Article
|
Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.
|
Academic Article
|
Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma.
|
Academic Article
|
The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
|
Academic Article
|
Pancreaticoduodenectomy with vascular resection for pancreatic head adenocarcinoma.
|
Academic Article
|
Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?
|
Academic Article
|
Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
|
Academic Article
|
The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.
|
Academic Article
|
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.
|
Academic Article
|
Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
|
Academic Article
|
Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy.
|
Academic Article
|
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma.
|
Academic Article
|
Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
|
Academic Article
|
The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
|
Academic Article
|
Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms.
|
Academic Article
|
Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?
|
Academic Article
|
A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma
|
Academic Article
|
Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
|
Academic Article
|
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma
|
Academic Article
|
Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality
|
Academic Article
|
Transforming growth factor-β limits secretion of lumican by activated stellate cells within primary pancreatic adenocarcinoma tumors
|
Academic Article
|
Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival
|
Academic Article
|
Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
|
Academic Article
|
Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
|
Academic Article
|
Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer.
|
Academic Article
|
A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma.
|
Academic Article
|
Transforming Growth Factor-? Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors.
|
Academic Article
|
Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
|
Academic Article
|
Quantitative imaging to evaluate malignant potential of IPMNs.
|
Academic Article
|
Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy.
|
Academic Article
|
Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality.
|
Academic Article
|
Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater.
|
Academic Article
|
Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
|
Academic Article
|
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.
|
Academic Article
|
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
|
Academic Article
|
Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma.
|
Academic Article
|
Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.
|
Academic Article
|
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
|
Academic Article
|
Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma.
|
Academic Article
|
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Multimodality management of borderline resectable pancreatic adenocarcinoma.
|
Academic Article
|
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.
|
Academic Article
|
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.
|
Academic Article
|
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.
|
Academic Article
|
Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
|
Academic Article
|
Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis.
|
Academic Article
|
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
|
Academic Article
|
Expression and Clinical Significance of Protein Kinase RNA-Like Endoplasmic Reticulum Kinase and Phosphorylated Eukaryotic Initiation Factor 2a in Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity.
|
Academic Article
|
Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression.
|
Academic Article
|
Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis.
|
Academic Article
|
Pancreaticoduodenectomy with Mesocaval Shunt for Locally Advanced Pancreatic Adenocarcinoma.
|
Academic Article
|
Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing.
|
Academic Article
|
Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection.
|
Academic Article
|
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.
|
Academic Article
|
Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma.
|
Academic Article
|
Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization.
|
Academic Article
|
Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma.
|
Academic Article
|
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
|
Academic Article
|
Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma.
|
Academic Article
|
Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update.
|
Academic Article
|
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
|
Academic Article
|
Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series.
|
Academic Article
|
Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Adherence with operative standards in the treatment of gastric cancer in the United States.
|
Academic Article
|
Home-Based Exercise Prehabilitation During Preoperative Treatment for Pancreatic Cancer Is Associated With Improvement in Physical Function and Quality of Life.
|
Academic Article
|
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma.
|
Academic Article
|
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer.
|
Academic Article
|
Response to the Comment on "Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma".
|
Academic Article
|
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis.
|
Academic Article
|
Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why?
|
Academic Article
|
Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.
|
Academic Article
|
Natural history and prognostic factors for localised small bowel adenocarcinoma.
|
Academic Article
|
Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study.
|
Academic Article
|
Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival.
|
Academic Article
|
Surgical Eligibility Does Not Imply Surgical Equity: Recommendations for Curative Treatment in Patients With Stage I/II Pancreatic Head Adenocarcinoma Differ by Age and Race.
|
Academic Article
|
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
|
Academic Article
|
Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
|
Academic Article
|
GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first.
|
Academic Article
|
AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing.
|
Academic Article
|
CES2 sustains HNF4a expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop.
|
Academic Article
|
NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience.
|
Academic Article
|
Contemporary Assessment of Need for Palliative Bypass After Aborted Pancreatoduodenectomy Following Neoadjuvant Therapy.
|
Academic Article
|
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
|
Academic Article
|
CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes.
|
Academic Article
|
Preoperative therapy for pancreatic adenocarcinoma-precision beyond anatomy.
|
Academic Article
|
Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first.
|
Academic Article
|
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
|
Academic Article
|
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
|
Academic Article
|
A patient-centered, multidisciplinary approach to treating borderline resectable pancreatic adenocarcinoma.
|
Academic Article
|
3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma.
|
Academic Article
|
Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma.
|
Academic Article
|
A decade's experience of managing suspected pancreatic adenocarcinoma at a tertiary cancer center.
|
Academic Article
|
Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy.
|
Academic Article
|
Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy.
|
Academic Article
|
Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma.
|
Academic Article
|
Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreatoduodenectomy.
|
Academic Article
|
Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501).
|
Academic Article
|
Prognostic significance of trophoblastic cell surface antigen 2 expression and pathologic parameters in patients with ampullary adenocarcinoma.
|
Academic Article
|
Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma.
|
Academic Article
|
Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinoma.
|
Academic Article
|
Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma.
|
Academic Article
|
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.
|
Academic Article
|
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
|
Academic Article
|
Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study.
|
Academic Article
|
ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9.
|
Academic Article
|
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.
|
Academic Article
|
Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas.
|